Immunomodulatory properties of thalidomide analogs: Pomalidomide and lenalidomide, experimental and therapeutic applications

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 5, Issue 3, 2011, Pages 192-196

  Bodera, Pawel ^a   Stankiewicz, Wanda ^a  

^a MILITARY INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Poland)

Author keywords

Cancer treatment; Immunomodulatory drugs (IMiDs); Lenalidomide; Pomalidomide

Indexed keywords

ANTIBODY CONJUGATE; COLCHICINE; CYCLOOXYGENASE 2; DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LENALIDOMIDE; PACLITAXEL; PHOSPHODIESTERASE IV; POMALIDOMIDE; REACTIVE OXYGEN METABOLITE; RHIZOXIN; RITUXIMAB; THALIDOMIDE DERIVATIVE; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE;

ADAPTIVE IMMUNITY; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B LYMPHOCYTE ACTIVATION; BIRTH DEFECT; CELL CYCLE ARREST; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COMPETITIVE INHIBITION; CYTOKINE RELEASE; DNA METHYLATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SYNTHESIS; ENDOPLASMIC RETICULUM; ERYTHROPOIESIS; EXTRACELLULAR MATRIX; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; LEPROSY; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUTROPENIA; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; OXIDATION REDUCTION REACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TERATOGENICITY; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOMODULATION; NEOPLASMS; PATENTS AS TOPIC; THALIDOMIDE;

EID: 80052830913     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221411797265890     Document Type: Review

References (26)

1. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000;75: 897-901.
2. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003;78:34-9.
3. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000;23:319-21.
4. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:2593-602.
5. Ng SS, MacPherson GR, Gutschow M, Eger K, Figg WD. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res 2004; 10; 4192.
6. Ando Y, Fuse E, Figg WD. Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 2002; 8:1964-73.
7. Ge Y, Montano I, Rustici G, Freebern WJ, Haggerty CM, Ponciano-Jackson D, et al. Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood 2006; 108: 4126-35.
8. Puskas LG, Fehér LZ, Vizler C, Ayaydin F, Rásó E, Molnár E, et al. Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis 2010; 9:56.
9. Teo SK. Properties of thalidomide and its analogues: Implications for anticancer therapy. Am Assoc Pharm Sci J 2005; 7: E14.
10. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163: 380.
11. Lepper ER, Ng SS, Gutschow M, Weiss M, Hauschildt S, Hecker TK, et al. Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. J Med Chem 2004;47: 2219-27.
12. Ng SS, Gütschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, et al. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res 2003;63:3189-94.
13. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1 Blood 2006;107, 8, 3098-105.
14. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314-22.
15. Davies FE, Raje N, Hideshima T. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98(1):210-6.
16. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application. Br J Haematol 2005; 128(2):192-203.
17. Escoubet-Lozach L, Lin I-L, Jensen-Pergakes K. Pomalidomide and lenalidomide induce p21WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009; 69(18); 7347-56.
18. List AF. Lenalidomide - the phoenix rises. N Engl J Med 2007; 357: 2183-6.
19. Zhu WG, Hileman T, Ke Y, Wang P, Lu S, Duan W, et al. 5-Aza- 2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem 2005; 279: 15161-6.
20. Gaidarova S, Corral LG, Glezer E, Schafer PH, Lopez-Girona A. Treatment of MCL cells with combined rituximab and lenalidomide enhances NK-mediated synapse formation and cell killing. Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 1687.
21. st ASH Annual Meeting and Exposition, Dec 5-8, 2009.
22. Sherif, S.F. Combination therapy to enhance NK cell mediated cytotoxicity priority claim. WO2010065939 (2010).
23. Toyohiro, T., Arakawa, K. A., Shinichi, T. Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated. WO2008070168 (2008).
24. Daelken, B., Uherek, C.H., Anderson, K, Hideshima, T., Bruecher, C. Methods and agents for improving targeting of CD138 expressing tumor cells. US20090169570 (2009).
25. Ni, J., Gentz, R.L, Yu, G-L, Su, J. Y, Rosen, C. A. Death domain containing receptor 5. US20080248046 (2008).
26. ClinicalTrials.gov: IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma, Available at: http://clinicaltrials.gov/show/ NCT01053949 on March 10, 2011 (Accessed on: March 10, 2011).